Abstract:Abstract MYC is one of the most validated driver oncogenes and is overexpressed in most human cancers. However, the MYC protein is considered “undruggable” due to its disordered structure and difficulties associated with targeting transcription factors. The MYC gene promoter forms G- quadruplex, a four-stranded non-canonical DNA secondary structure. The MYC G-quadruplex functions as a transcription silencer and further inhibits MYC expression upon drug binding, representing an exciting approach for MYC-targeting cancer therapy. Indenoisoquinolines are topoisomerase I inhibitors with better physicochemical and biological properties than the clinical camptothecin drugs. We previously revealed a novel mechanism of action for active anticancer indenoisoquinolines by dual inhibition of MYC and topoisomerase I, where potent MYC inhibition was achieved through targeting its promoter G-quadruplex. Herein, we report the design, cellular activity, and in vivo efficacy of novel anticancer 7-aza-8,9-methylenedioxyindenoisoquinoline derivatives based on optimized substituents and π-π stacking interactions. Using biophysical, biochemical, and cellular assays, we demonstrated that the new indenoisoquinoline derivatives greatly stabilized the MYC promoter G-quadruplex, significantly lowered MYC protein and mRNA levels in cancer cells, and inhibited topoisomerase I activity. A MYC G-quadruplex mediated mechanism of action was evident by differential activities in Raji vs CA-46 cells. The importance of MYC targeting was corroborated by potent cytotoxicity against a panel of MYC-dependent cancer cell lines as well as the NCI-60 panel of human cancer cell lines. The top three candidates were evaluated for pharmacokinetics and in vivo anticancer properties. Excellent metabolic stability, bioavailability, and tumor accumulation were observed in xenograft mouse models. Potent and significant tumor growth inhibition was demonstrated in the aggressive RD-ES Ewing Sarcoma xenograft mouse model while the drugs were well-tolerated. In addition, favorable brain penetration and pharmacokinetics were established, which encourage future evaluations in difficult-to-treat brain tumors. In conclusion, we designed and developed 7-aza-8,9-methylenedioxyindenoisoquinoline derivatives that are dual inhibitors of MYC and topoisomerase I. Our drug candidates demonstrated excellent pharmacokinetics and in vivo anticancer activities with promising indications in MYC-dependent cancers. Citation Format: Yichen Han, Luying Chen, Adam Buric, Venkat Chintareddy, Pooran Chand, Randall Riggs, Mark Cushman, Danzhou Yang. Design and anticancer biological evaluation of novel 7-aza-8,9-methylenedioxyindenoisoquinoline derivatives that inhibit MYC and topoisomerase I [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5964.

Identification of 5-Thiocyanatothiazol-2-amines Disrupting WDR5-MYC Protein-Protein Interactions.

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (wdr5)–mixed Lineage Leukemia (MLL) Protein–Protein Interaction

Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction.

Inhibition of Ciap1 As a Strategy for Targeting C-Myc-driven Oncogenic Activity.

Molecular Insights into the Specific Targeting of c-MYC G-Quadruplex by Thiazole Peptides

High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction.

Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer

Recent Progress in Modulation of WD40-Repeat Domain 5 Protein (WDR5): Inhibitors and Degraders

Identification of a Novel C-Myc Inhibitor 7594-0037 by Structure-Based Virtual Screening and Investigation of Its Anti-Cancer Effect on Multiple Myeloma

Modes of Action of a Novel c-MYC Inhibiting 1,2,4-Oxadiazole Derivative in Leukemia and Breast Cancer Cells

Turning Up the Heat on MYC: Progress in Small-Molecule Inhibitors

Exploring promising natural compounds for breast cancer treatment: in silico molecular docking targeting WDR5-MYC protein interaction

Loss of Wdr5 attenuates MLL-rearranged leukemogenesis by suppressing Myc targets

Design, Synthesis, and Evaluation of New Selective NM23-H2 Binders as c-MYC Transcription Inhibitors via Disruption of the NM23-H2/G-Quadruplex Interaction

A Selective Small‐Molecule c‐Myc Degrader Potently Regresses Lethal c‐Myc Overexpressing Tumors

Constructing triazole-modified quinazoline derivatives as selective c-MYC G-quadruplex ligands and potent anticancer agents through click chemistry

Discovery of Tetrahydropyrazolopyrazine Derivatives as Potent and Selective MYT1 Inhibitors for the Treatment of Cancer

The WD repeat-containing protein 5 (WDR5) antagonist WDR5-0103 restores the efficacy of cytotoxic drugs in multidrug-resistant cancer cells overexpressing ABCB1 or ABCG2

Comprehensive Omics Analysis of a Novel Small-Molecule Inhibitor of Chemoresistant Oncogenic Signatures in Colorectal Cancer Cell with Antitumor Effects

Abstract 5964: Design and anticancer biological evaluation of novel 7-aza-8,9-methylenedioxyindenoisoquinoline derivatives that inhibit MYC and topoisomerase I

Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1,2,3-thiadiazoles as microtubule-destabilizing agents